Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer

Cancer

Volumn 118, Issue 4, 2012, Pages 1062-1074

  Inoue, Keiji ^a   Fukuhara, Hideo ^a   Shimamoto, Tsutomu ^a   Kamada, Masayuki ^a   Iiyama, Tatsuo ^a   Miyamura, Mitsuhiko ^a   Kurabayashi, Atsushi ^a   Furihata, Mutsuo ^a   Tanimura, Masanobu ^b   Watanabe, Hironobu ^c   Shuin, Taro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b Chikamori Hospital   (Japan)

^c Kochi   (Japan)

Author keywords

5 aminolevulinic acid; administration route; intravesical recurrence; nonmuscle invasive bladder cancer; photodynamic diagnosis

Indexed keywords

AMINOLEVULINIC ACID;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHOTODYNAMICS; PHOTOSENSITIVITY DISORDER; PHYSICAL TOLERANCE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SURGICAL APPROACH; SURVIVAL RATE; URINARY FREQUENCY; URINARY URGENCY; VOMITING; BLADDER SURGERY; CANCER DIAGNOSIS; CANCER RECURRENCE; ENDOSCOPY; FLUORESCENCE IMAGING; INTRAOPERATIVE PERIOD; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC DIAGNOSIS; TRANSURETHRAL RESECTION OF BLADDER TUMOR;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CYSTECTOMY; FEMALE; FLUORESCENCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOTOSENSITIZING AGENTS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84856787098     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26378     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002; 38: 99-166.
3. Matsuda T, Marugame T, Kamo K, et al. The Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2011; 41: 139-147.
4. Lee R, Droller MJ,. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 2000; 27: 1-13, vii.
5. Navone NM, Polo CF, Frisardi AL, et al. Heme biosynthesis in human breast cancerâmimetic "in vitro" studies and some heme enzymic activity levels. Int J Biochem. 1990; 22: 1407-1411.
6. Fukuda H, Paredes S, Batlle AM,. Tumour-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp Biochem Physiol B. 1992; 102: 433-436.
7. Steinbach P, Weingandt H, Baumgartner R, et al. Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol. 1995; 62: 887-895.
8. Baumgartner R, Fisslinger H, Jocham D, et al. A fluorescence imaging device for endoscopic detection of early stage cancerâinstrumental and experimental studies. Photochem Photobiol. 1987; 46: 759-763.
9. Krammer B, Plaetzer K,. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci. 2008; 7: 283-289.
10. Kriegmair M, Baumgartner R, Knuechel R, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994; 44: 836-841.
11. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996; 155: 105-109.
12. Koenig F, McGovern FJ, Larne R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int. 1999; 83: 129-135.
13. Riedl CR, Plas E, Pfluger H,. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. J Endourol. 1999; 13: 755-759.
14. Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol. 1999; 13: 117-121.
15. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology. 2001; 57: 690-694.
16. Zaak D, Hungerhuber E, Schneede P, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer. 2002; 95: 1234-1238.
17. Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology. 2007; 69: 260-264.
18. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol. 2002; 168: 67-71.
19. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant reduction of recurrence of superficial bladder tumor with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. Urologe A. 2003; 42: 1366-1373.
20. Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005; 174: 2129-2133.
21. Babjuk M, Soukup V, Petrik R, et al. Fluorescence cystoscopy in the diagnostics and treatment of superficial urinary bladder tumors. Cas Lek Cesk. 2005; 144: 15-18.
22. Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007; 69: 675-679.
23. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010; 184: 1907-1913.
24. Hermann GG, Mogensen K, Carlsson S, et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized 2-centre study. BJU Int. [published online ahead of print March 17, 2011.]
25. Schumacher MC, Holmang S, Davidsson T, et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2010; 57: 293-299.
26. Burger M, Stief CG, Zaak D, et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology. 2009; 74: 1282-1286.
27. Common Terminology Criteria for Adverse Events version 3.0. Inter J Clin Oncol. 2004; 9 (suppl III): 1-82.
28. Miyoshi N, Ogasawara T, Ogawa T, et al. An application of fluorescence analysis of metabolized protoporphyrin-IX (Pp-IX) in a tumor tissue administrated with 5-aminolevulinic acid (5-ALA). J Jpn Soc Laser Med. 2002; 23: 81-88.
29. Inoue K, Karashima T, Kamada M, et al. Clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis using fluorescence cystoscopy for bladder cancer. Nippon Hinyokika Gakkai Zasshi. 2006; 97: 719-729.
30. Inoue K, Kuno T, Fukuhara H, et al. Clinical experience with transurethral resection of bladder tumor (TUR-Bt) guided by photodynamic diagnosis (PDD). Nippon Hinyokika Gakkai Zasshi. 2009; 100: 661-670.
31. Japan Urological Association. General Rule for Clinical and Pathological Studies on Bladder Cancer. 3rd ed. Tokyo, Japan: Kanehara Publication; 2001.
32. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008.
33. Utsuki S, Miyoshi N, Oka H, et al. Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study. Brain Tumor Pathol. 2007; 24: 53-55.
34. Kriegmair M, Zaak D, Stepp H, et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol. 1999; 36: 386-392.
35. Filbeck T, Pichlmeier U, Knuechel R, et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology. 2002; 60: 1025-1028.
36. Riedl CR, Daniltchenko D, Koenig F, et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol. 2001; 165: 1121-1123.
37. Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol. 2002; 168: 475-478.
38. Stanislaus P, Zaak D, Stadler T, et al. Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. World J Urol. 2010; 28: 407-411.
39. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 2003; 170: 428-432.
40. Dalton JT, Yates CR, Yin D, et al. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther. 2002; 301: 507-512.